News
-
-
PRESS RELEASE
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio -
-
PRESS RELEASE
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress -
-
PRESS RELEASE
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia -
-
PRESS RELEASE
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy -
-
PRESS RELEASE
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study
